印度尼西亚耐利福平/耐多药结核病患者使用高剂量异烟肼的药代动力学与药效学研究
该观察性药代动力学研究纳入40例接受含高剂量异烟肼(10–15 mg/kg/日)标准化方案治疗的印尼成人耐利福平/耐多药肺结核患者,评估异烟肼暴露达标情况并探索暴露-反应关系。几何均值AUC0-24为35.4 h·mg/L、Cmax为8.5 mg/L;26例有MIC数据者中不足25%达到AUC0-24/MIC≥85和Cmax/MIC≥17.5的目标。较低AUC0-24与痰培养转阴延迟(>2个月)相关(校正OR 0.18,95%CI 0.04–0.89)。
要点
- 40例患者异烟肼几何均值AUC0-24为35.4 h·mg/L,Cmax为8.5 mg/L。
- 26例有MIC数据者中仅6例达AUC0-24/MIC≥85、5例达Cmax/MIC≥17.5。
- 较低AUC0-24与痰培养转阴延迟(>2个月)相关,校正OR 0.18(95%CI 0.04–0.89)。
核心结论
- 多数患者异烟肼暴露低于目标值,某些低暴露风险组可能需要调整剂量。
- 低异烟肼暴露对培养转阴延迟的影响值得关注。
研究设计与样本
- 在印度尼西亚18–65岁成人肺耐利福平/耐多药结核患者中开展的观察性药代动力学研究,含探索性药代动力学/药效学分析。
- 患者接受含高剂量异烟肼(10–15 mg/kg/日)的标准化方案治疗9–11个月。
- 治疗≥2周后行密集药代动力学采样,采用非房室分析评估总血浆药物暴露(AUC0-24)和峰浓度(Cmax)。
- 连续纳入40例患者(中位年龄37.5岁)。
- 采用多变量线性回归和逻辑回归分别识别药物暴露和反应的预测因素。
主要发现
- 异烟肼AUC0-24几何均值为35.4 h·mg/L,Cmax几何均值为8.5 mg/L。
- 较低AUC0-24和Cmax与慢乙酰化表型以外者相关(P < 0.05),较低Cmax与男性相关。
- 26例有MIC数据者中,达到AUC0-24/MIC目标者6/26例、达到Cmax/MIC目标者5/26例,均不足25%。
- 较低异烟肼AUC0-24与痰培养转阴延迟(治疗>2个月)相关,校正OR 0.18(95%CI 0.04–0.89)。
关键数值与推荐
- 暴露目标:异烟肼AUC0-24/MIC比值为85,Cmax/MIC比值为17.5。
- 高剂量异烟肼剂量为10–15 mg/kg/日,疗程9–11个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients. METHODS: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months. Intensive pharmacokinetic sampling was performed after ≥2 weeks of treatment. Total plasma drug exposure (AUC0-24) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC0-24/MIC ratio of 85 and Cmax/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. RESULTS: We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC0-24 and Cmax were 35.4 h·mg/L and 8.5 mg/L, respectively. Lower AUC0-24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC0-24/MIC (n = 6/26) and Cmax/MIC (n = 5/26). Lower isoniazid AUC0-24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04-0.89)]. CONCLUSIONS: Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.
引用
- Yunivita V, Gafar F, Santoso P, et al. Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia. J Antimicrob Chemother. 2024. PMID: 38459759. doi:10.1093/jac/dkae057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。